TSHA News and Press, Taysha Gene Therapies Inc. From 06/18/24

Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging safety profile seen across adult (up to 52 weeks) and pediatric (up to 22 weeks) patients with differ...

Company to host webcast on Tuesday, June 18, 2024, at 8:00 AM Eastern Time Oral presentation by Elsa Rossignol, M.D., FRCP, FAAP, Principal Investigator of the REVEAL adolescent and adult trial at CHU Sainte-Justine and Colleen Buhrfiend, M.D., of RUSH University Medical Center at ...

2024-06-11 11:02:57 ET More on Neurogene Neurogene Stock: Gene Therapy Specialist May Break Chain Of Failed Mergers Historical earnings data for Neoleukin Therapeutics Financial information for Neoleukin Therapeutics Read the full article on Seeking Alpha ...

2024-05-28 13:15:05 ET Piper Sandler analyst issues MARKET OUTPERFORM recommendation for TSHA on May 28, 2024 11:00AM ET. The previous analyst recommendation was Market Outperform. TSHA was trading at $3.145 at issue of the analyst recommendation. The overall analyst con...

2024-05-28 13:15:05 ET Needham analyst issues UNDERPERFORM recommendation for TSHA on May 28, 2024 11:00AM ET. The previous analyst recommendation was Underperform. TSHA was trading at $3.145 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-05-15 04:55:23 ET Taysha Gene Therapies, Inc. (TSHA) Q1 2024 Earnings Conference Call May 14, 2024, 4:30 PM ET Company Participants Hayleigh Collins - Director, Head of Corporate Communications and Investor Relations Sean Nolan - Chief Executive Officer and Chai...

2024-05-14 16:10:06 ET More on Taysha Gene Therapies Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript Taysha Gene Therapies, Inc. 2023 Q4 - Results - Earnings Call Presentation ...

Completed dosing in cohort one (low dose, 5.7x10 14 total vg) of REVEAL Phase 1/2 adolescent and adult trial with longer-term data supporting the safety profile and durable response of TSHA-102; enrolled first patient in cohort two (high dose, 1x10 15 total vg) with dosing...

2024-05-14 12:45:25 ET More on Taysha Gene Therapies Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript Taysha Gene Therapies, Inc. 2023 Q4 - Results - Earnings Call Presentation ...

2024-05-13 17:35:36 ET More on Taysha Gene Therapies Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript Taysha Gene Therapies, Inc. 2023 Q4 - Results - Earnings Call Presentation ...